A new industry report confirms that peptides are driving the next era of obesity treatment. The Obesity – Competitive Landscape and Clinical Trial Analysis, 2026 review, covering more than 200 companies and 200 investigational drugs, highlights a decisive shift toward oral, multi‑agonist, and ultra‑long‑acting peptide therapies.
Peptides at the Core of Obesity Innovation
Obesity is now recognized as a chronic, relapsing disease with wide‑ranging complications. While lifestyle interventions remain essential, pharmacotherapy is increasingly peptide‑based. GLP‑1 receptor agonists such as semaglutide (Wegovy) have already transformed the market, but the report shows that the next wave of innovation lies in multi‑agonist peptides and new dosing formats.
Recent clinical milestones include:
- Retatrutide (Eli Lilly), a triple agonist targeting GLP‑1, GIP, and glucagon receptors, with Phase III data showing substantial weight loss and metabolic improvements.
- Enicepatide/CT‑388 (Roche), a dual GLP‑1/GIP agonist, reporting mean body‑weight reductions of up to 22.7% at 48 weeks.
- ASC36 (Ascletis Pharma), an amylin receptor peptide agonist designed for once‑monthly or quarterly dosing.
- MBX 4291 (MBX Biosciences), showing early Phase I evidence of 7% weight loss at eight weeks with potential monthly dosing.
These candidates illustrate how peptide engineering is enabling less frequent dosing, lean‑mass preservation, and novel mechanisms beyond traditional incretin therapy.
Oral Peptides Enter Mainstream
The report also highlights the rise of oral peptide formulations. Orforglipron, Eli Lilly’s once‑daily oral GLP‑1 receptor agonist, received UK regulatory approval in August 2026. Novo Nordisk’s oral semaglutide achieved approximately 17% mean weight loss at 64 weeks in the Phase III OASIS 4 trial, proving oral peptides can match injectable efficacy.
For patients, oral dosing represents a breakthrough in accessibility and adherence, removing barriers associated with injections and aligning with preferences for convenient daily therapy.
Competitive Landscape
The report profiles leading players including Eli Lilly, Novo Nordisk, Roche, Ascletis Pharma, Viking Therapeutics, MBX Biosciences, and Neurocrine Biosciences. Strategic activity spans licensing deals, collaborations, and acquisitions, reflecting intense competition to dominate the peptide obesity market.
With obesity affecting hundreds of millions worldwide, the stakes are enormous. Analysts note that peptide therapies are not only expanding the treatment toolbox but also redefining commercial strategies, as companies race to secure leadership in oral and long‑acting peptide formats.
Outlook
The obesity drug pipeline is evolving rapidly, but one theme is clear: peptides are the backbone of next‑generation therapies. From GLP‑1 analogues to multi‑agonist constructs and amylin receptor agonists, peptide science is driving efficacy, safety, and patient‑friendly dosing. As oral and ultra‑long‑acting peptides move closer to market, obesity treatment is entering a new era where convenience and innovation converge.
1 Response